Elsevier

Clinical Therapeutics

Volume 27, Issue 12, December 2005, Pages 1859-1884
Clinical Therapeutics

New drug review
Tinidazole: A nitroimidazole antiprotozoal agent

https://doi.org/10.1016/j.clinthera.2005.12.012Get rights and content

Abstract

Background:

Tinidazole, a structural analogue of metrondazole, is an antiprotozoal agent that has been widely used in Europe and developing countries for >2 decades with established efficacy and acceptable tolerability. It was recently approved by the US Food and Drug Administration for the treatment of trichomoniasis, giardiasis, amebiasis, and amebic liver abscess.

Objective:

This article reviews the pharmacologicand pharmacokinetic properties and clinical usefulness of tinidazole.

Methods:

Relevant information was identified through a search of MEDLINE (1966–August 2005), Iowa Drug Information Service (1966–August 2005), and International Pharmaceutical Abstracts (1970–August 2005) using the terms tinidazole, Fasigyn, and nitroimidazole.

Results:

In vitro, tinidazole exhibits activity againstpathogenic protozoa (eg, Tricbomonas vaginalis, Entamoeba bistolytica, Giardia duodenalis), a wide range of clinically significant anaerobic bacteria (eg, Bacteroides fragilis, Clostridium difficile), and the microaerophilic bacterium Helicobacter pylori. In susceptible protozoal and bacterial cells, tinidazole is reduced to cytotoxic intermediates that covalently bind to DNA, causing irreversible damage. In human adults, tinidazole had a bioavailability of 100% and a Vd of 50.7 L, was minimally bound to plasma protein (12%), had a plasma elimination t½ of 12.3 hours, and was eliminated primarily by hepatic metabolism (∼63%). Dose adjustment does not appear to be necessary on the basis of race, sex, or renal function. No data were found on the disposition of tinidazole in patients with hepatic insufficiency; therefore, use of tinidazole in patients with severe hepatic impairment (Child-Pugh class C) is not recommended. Clinical cure rates in patients with trichomoniasis, giardiasis, amebiasis, and amebic liver abscess were generally >90%. In comparative trials, tinidazole was as effective as metronidazole in the treatment of trichomoniasis and was significantly more effective than metronidazole in the treatment of giardiasis (P < 0.05) and amebiasis (P < 0.05). The most commonly reported (>1%) adverse effects included bitter taste, nausea, abdominal discomfort, anorexia, vomiting, and fatigue. The recommended dosage of tinidazole is a single dose of 2 g for trichomoniasis and giardiasis, and 2 g/d for 3 to 5 days for amebiasis.

Conclusions:

Tinidazole appears to be a promisingagent for the treatment of trichomoniasis, giardiasis, amebiasis, and amebic liver abscess. Clinical studies are needed to evaluate the use of tinidazole against anaerobic bacteria and H pylori.

References (85)

  • NordC.E. et al.

    Tinidazole-microbiology, pharmacology and efficacy in anaerobic infections

    Infection

    (1983)
  • RaetherW. et al.

    Nitroheterocyclic drugs with broad spectrum activity

    Parasitol Res

    (2003)
  • ReesP.H. et al.

    Single-dose treatment of vaginal trichomoniasis with tinidazole

    East Afr Med J

    (1974)
  • GardnerT.B. et al.

    Treatment of giardiasis

    Clin Microbiol Rev

    (2001)
  • TsacaT. et al.

    Effects of metronidazole and tinidazole on NTPDase1 and ecto-5′ nucleotidase from intact cells of Trichomonas vaginalis

    FEMS Microbiol Lett

    (2003)
  • SearsS.D. et al.

    In vitro susceptibility of Trichomonas vaginalis to 50 antimicrobial agents

    Antimicrob Agents Chemother

    (1988)
  • ChintanaT. et al.

    In vitro studies on the sensitivity of local Entamoeba histolytica to anti-amoebic drugs

    Southeast Asian J Trop Med Public Health

    (1986)
  • GordtsB. et al.

    In vitro susceptibilities of 25 Giardia lamblia isolates of human origin to six commonly used antiprotozoal agents

    Antimicrob Agents Chemother

    (1985)
  • BerganT.

    Antibacterial activity and pharmacokinetics of nitroimidazoles: A review

    Scand J Infect Dis Suppl

    (1985)
  • JokipiiA.M. et al.

    Comparative activity of metronidazole and tinidazole against Clostridium difcile and Peptostreptococcus anaerobius

    Antimicrob Agents Chemother

    (1987)
  • CrowellA.L. et al.

    In vitro metronidazole and tinidazole activities against metronidazole resistant strains of Trichomonas vaginalis

    Antimicrob Agents Chemother

    (2003)
  • LooV.G. et al.

    Helicobacter pylori infection in a pediatric population: In vitro susceptibilities to omeprazole and eight antimicrobial agents

    Antimicrob Agents Chemother

    (1992)
  • FalsafiT. et al.

    Susceptibilities to different antibiotics of Helicobacter pylori strains isolated from patients at the pediatric medical center of Tehran, Iran

    J Clin Microbiol

    (2004)
  • KharsanyA.B. et al.

    Antimicrobial susceptibilities of Gardnerella vaginalis

    Antimicrob Agents Chemother

    (1993)
  • MattilaJ. et al.

    Comparative pharmacokinetics of metronidazole and tinidazole as influenced by administration route

    Antimicrob Agents Chemother

    (1983)
  • WoodB.A. et al.

    Pharmacokinetics of tinidazole and metronidazole in women after single large oral doses

    Brit J Vener Dis

    (1975)
  • ChaikinP. et al.

    Pharmacokinetics of tinidazole in male and female subjects

    J Clin Pharmacol

    (1982)
  • WoodB.A. et al.

    The pharmacokinetics, metabolism and tissue distribution of tinidazole

    J Antimicrob Chemother

    (1982)
  • ViitanenJ. et al.

    Concentrations of metronidazole and tinidazole in male genital tissues

    Antimicrob Agents Chemother

    (1985)
  • MannistoP. et al.

    Concentrations of metronidazole and tinidazole in female reproductive organs after a single intravenous infusion and after repeated oral administration

    Infection

    (1984)
  • Von KonowL. et al.

    Concentrations of tinidazole and metronidazole in serum, saliva and alveolar bone

    J Antimicrob Chemother

    (1982)
  • RipaT. et al.

    Concentrations of tinidazole in body fluids and tissues in gynaecological patients

    Chemotherapy

    (1977)
  • JokipiiA.M. et al.

    Penetration of the blood brain barrier by metronidazole and tinidazole

    J Antimicrob Chemother

    (1977)
  • LiX.Q. et al.

    Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitrodata

    Eur J Clin Pharmacol

    (2003)
  • WoodS.G. et al.

    Pharmacokinetics and metabolism of 14C-tinidazole in humans

    J Antimicrob Chemother

    (1986)
  • RobsonR.A. et al.

    Tinidazole pharmacokinetics in severe renal failure

    Clin Pharmacokinet

    (1984)
  • FlouvatB.L. et al.

    Pharmacokinetics of tinidazole in chronic renal failure and in patients on hemodialysis

    Br J Clin Pharmacol

    (1983)
  • CarmineA.A. et al.

    Tinidazole in anaerobic infections: A review of its antibacterial activity, pharmacological properties and therapeutic efficacy

    Drugs

    (1982)
  • MatiJ.K. et al.

    The treatment of trichomonal vaginitis using a single dose of tinidazole by mouth

    East Afr Med J

    (1974)
  • ApteV.V. et al.

    Tinidazole in the treatment of trichomoniasis, giardiasis and amoebiasis. Report of a multicentre study

    Drugs

    (1978)
  • GabrielG. et al.

    Single dose treatment of trichomoniasis

    J Int Med Res

    (1982)
  • Cited by (134)

    • Solubility, thermodynamic properties and molecular simulation of tinidazole in fourteen mono-solvents at different temperatures

      2022, Journal of Chemical Thermodynamics
      Citation Excerpt :

      Tinidazole (TNZ) [IPUAC: 1-(2-ethylsulfonylethyl)-2-methyl-5-nitroimidazole, CAS number: 19387-91-8, Fig. 1; Molar mass: 247.27 g·mol−1], which belongs to nitroimidazoles and is widely used in the prevention and treatment of anaerobes and protozoal diseases [1,2].

    • US FDA-Approved Antibiotics During the 21st Century

      2022, Encyclopedia of Infection and Immunity
    View all citing articles on Scopus
    View full text